Indegene Limited — PPTs, 28-04-2025: Investor Presentation

### Financial Highlights:

Indegene reported strong financial performance for the recent quarter, with revenue from operations at INR 7,556 Mn, marking a 12.3% YoY increase. The consolidated annual revenue grew by 9.6% YoY, reaching INR 28,393 Mn. In terms of profitability, the PAT margin hit 15.6% for Q4, with a total PAT for the year exceeding INR 400 Cr, a notable growth of 20.8% YoY. Strong EBITDA margins were maintained at 20.2% for the quarter and 19.8% for the year, reflecting effective cost management.

### Strategic Initiatives & Growth Drivers:

The company launched its GenAI platform, Cortex, enhancing its technology-driven service offerings. Indegene's strategic focus remains on expanding its client base while driving efficiencies in existing accounts. The company is capitalizing on the growing outsourcing market and digital adoption trends in the life sciences sector.

### Business Developments:

Indegene is actively strengthening client relationships, including 73 active clients, with significant revenue contributions from large biopharma companies. The company recently hosted an Investor Day that showcased its technological advancements and growth roadmap.

### Market Position & Competitive Advantage:

Indegene holds a robust leadership position in the healthcare and tech intersection, benefiting from deep healthcare expertise and a scalable operating model. Approximately 66% of revenue comes from the top 20 global biopharma clients, emphasizing strong market penetration.

### Investor Implications:

Indegene's steady revenue growth, impressive margins, and strategic technology investments present positive growth potential for investors. However, macroeconomic challenges should be monitored closely as the company navigates its expansion and execution strategies.